Committee on Science, Space, and Technology U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5)

Required by House Rule AI, Clause 2(g)(5)		
1. Your Name: CUNTON T, RUBIN		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No
3. Are you testifying on behalf of an entity that is not a government entity?	Yes	No
4. Other than yourself, please list which entity or entities you are represe	enting:	
5. Please list any Federal grants, cooperative agreements, or contracts (in subgrants or subcontracts) that you or the entity you represent have rafter October 1, 2013:	_	or
PLEASE SEE ATTACHED UST	a.	
 6. Please list any foreign government payments that you or the entity you received on or after October 1, 2013: 7. If your answer to the question in item 3 in this form is "yes," please desposition or representational capacity with the entity(ies) you are representational capacity with the entity(ies). 	cribe your	
8. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No
9. If the answer to the question in item 3 is "yes," please list any Federal g cooperative agreements, or contracts (including subgrants or subcontracted by the entities listed under the question in item 4 on or after that exceed 10 percent of the revenue of the entities in the year received source and amount of each grant or contract to be listed:	racts) that October 1,	2013,
I certify that the above information is true and correct. Signature: Date:	i. 1.17	

Clinton T. Rubin, Ph.D.

SUNY Distinguished Professor
Chair, Department of Biomedical Engineering
Director, Center for Advanced Technology in Medical Biotechnology
Bioengineering Building, Rm 217
Stony Brook University
Stony Brook, New York 11794-2580

Current Federal Funding

- National Institutes of Health (U-grant; NIH-REACH). Establishing a Long-Island Bioscience Hub (LIBH). April 2015-March 2019. \$3,000,000 through REACH, \$5.4M in NYS-based match. Total costs, \$8.4M. C. Rubin, Principal Investigator.
- National Institutes of Health (RO1). Augmentation of trabecular bone by low magnitude strain. December 1996-August 2016; \$4,294,209. C. Rubin, Principal Investigator (competitive renewal under review)
- National Institutes of Health (RO1). Harnessing Mechanical Signals to Define Mesenchymal Stem Cell Fate. Sept 2012-August 2017; \$1,945,000. C. Rubin, Principal Inv. (competitive renewal under review)
- U.S. Economic Development Administration. I6: Mentorship as a Driver of Entrepreneurship, Venture Creation, and SBIR/STTR Success in the Long Island, NY Region. December 2016 November 2019. \$500,000. C. Rubin, Principal Investigator.
- Department of Defense Breast Cancer Research Program (BCRP) Breakthrough Award: Effect of Low-Magnitude Mechanical Signals on Breast Cancer Bone Metastases. October 2015-September 2018. \$1,550,000. T. Guise & W. Thompson, Principal Investigators, C. Rubin, Co-Investigator
- National Health and Medical Research Council (Australia): Enhancing Osteoporosis Drug Treatment with Low Intensity Vibration. September 2016 August 2019. \$1,000,000 (Au). B. Beck, Principal Investigator, C. Rubin, Co-Investigator

False Statements Act Certification

You are specifically advised that providing false information to this Committee/Subcommittee, or concealing material information from this Committee/Subcommittee, is a crime, and you can be punished for that. If you acknowledge this, please sign the bottom of this form and return to the Committee. This form will be made part of the hearing record.

Witness signature

Date

4.27.17